Back to top
more

Jazz Pharmaceuticals (JAZZ)

(Delayed Data from NSDQ)

$104.48 USD

104.48
756,435

-1.26 (-1.19%)

Updated Jun 4, 2024 04:00 PM ET

After-Market: $104.53 +0.05 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (81 out of 249)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here is Why Growth Investors Should Buy Jazz (JAZZ) Now

by Zacks Equity Research

Jazz (JAZZ) possesses solid growth attributes, which could help it handily outperform the market.

Bet on These 5 High Earnings Yield Stocks to Book Profits

by Zacks Equity Research

Check out these five high earnings yield stocks for a powerful portfolio.

Are Investors Undervaluing Jazz Pharmaceuticals (JAZZ) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Jazz Pharma (JAZZ) Q3 Earnings Beat, Xyrem Drives Sales

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) beats third-quarter 2019 earnings and revenue estimates and raises its guidance for 2019.

Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Jazz (JAZZ) delivered earnings and revenue surprises of 14.21% and 2.87%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

ImmunoGen (IMGN) Q3 Earnings & Sales Beat, Shares Rally

by Zacks Equity Research

ImmunoGen (IMGN) reports narrower-than-expected third-quarter loss and beats revenue estimates. The company is set to initiate the FDA recommended phase III study on mirvetuximab soravtansine by year-end.

What's in the Cards for Teva (TEVA) This Earnings Season?

by Zacks Equity Research

Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q3 sales

Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More

by Zacks Equity Research

Let us take a look at five drug/biotech companies, which are supposed to release their quarterly results on Nov 5.

WIll Allergan (AGN) Beat Estimates This Earnings Season?

by Zacks Equity Research

Allergan's (AGN) key products like Botox are likely to have provided top-line support in Q3 as loss of exclusivity of several products hurts sales.

Is a Beat in the Cards for Mallinckrodt (MNK) in Q3 Earnings?

by Zacks Equity Research

Investors are looking forward to the performance of Specialty Brands and other pipeline updates, when Mallinckrodt (MNK) reports Q3 results.

Is a Beat in the Cards for Regeneron (REGN) Q3 Earnings?

by Zacks Equity Research

Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates, when Regeneron (REGN) reports third-quarter 2019 results.

Bristol-Myers (BMY) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Bristol-Myers (BMY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Guardant Health (GH) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

During Guardant Health's (GH) Q3 conference call, investors will watch out for the latest news on the colorectal cancer screening rates of its LUNAR-2 blood test.

Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalyst Pharma (CPRX) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

During Catalyst's (CPRX) third-quarter 2019 conference call, investor focus will be on the sales performance of its only marketed drug Firdapse and its label expansion studies.

Zacks.com featured highlights include: Koppers, Alaska Air, Guess?, Lionsgate and Jazz Pharmaceuticals

by Zacks Equity Research

Zacks.com featured highlights include: Koppers, Alaska Air, Guess?, Lionsgate and Jazz Pharmaceuticals

Invest in These 5 High Earnings Yield Stocks Right Away

by Zacks Equity Research

Here are five stocks with high earnings yield that can be picked for a solid portfolio.

5 Drug/Biotech Stocks Likely to Surpass on Earnings in Q3

by Zacks Equity Research

Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the third quarter.

Baxter (BAX) Misses Q3 Revenue Estimates, Issues Guidance

by Zacks Equity Research

Higher revenues, growth in all geographic segments and strong fourth-quarter 2019 revenue outlook benefit Baxter's (BAX) Q3 preliminary operating results. However, gross margin contraction remains a woe.

Why the Earnings Surprise Streak Could Continue for Jazz (JAZZ)

by Zacks Equity Research

Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

by Zacks Equity Research

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

Zoetis (ZTS) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Jazz Starts CAR T-cell Linked Neurotoxicity Study Enrollment

by Zacks Equity Research

Jazz (JAZZ) enrolls first patient in a mid-stage study to evaluate defibrotide in prevention of neurotoxicity in relapsed/refractory DLBCL patients receiving CAR T-cell therapy.

5 High Earnings Yield Stocks to Buy for a Rewarding Portfolio

by Zacks Equity Research

Here are five stocks with high earnings yield that can be picked for a solid portfolio.

Jazz Pharmaceuticals Enters Oversold Territory

by Zacks Equity Research

Jazz Pharmaceuticals plc (JAZZ) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.